April 7, 2014

Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration has approved Pradaxa (dabigatran etexilate mesylate), which is used to treat deep venous thrombosis and pulmonary embolism.

August 15, 2013

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital on a long-term study program to assess comparative effectiveness and safety, as well as prescribing patterns, of oral anticoagulants, including Pradaxa, for the reduction of stroke risk in U.S. patients with non-valvular atrial fibrillation.

October 19, 2010

The Food and Drug Administration approved a drug for preventing strokes and blood clots in...

September 20, 2010

A Food and Drug Administration advisory committee has recommended approval of a drug for patients...

July 6, 2010

Launch and use of new heart drugs will drive the market for drugs to treat...